Page 3 - Belgian Transparency News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on September 14, 2023, from Atlas Special Oppor

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 1, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...

Regulated Information Leuven, BELGIUM, Boston, MA, US – August 23, 2023 – 8.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...

Regulated Information Leuven, BELGIUM, Boston, MA, US – August 23, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Regulated Information Leuven, BELGIUM, Boston, MA, US – August 21, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...